MS Flashcards

1
Q

What is the definition of MS?

A

Multiple sclerosis (MS) is an autoimmune, cell-mediated demyelinating disease of the central nervous system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology of MS

A
  • The estimated prevalence of MS in England and Wales is 180 per 100,000
  • F>M
  • Most commonly diagnosed in 20-40 year olds
  • More common in white populations
  • More common in northern latitudes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the Risk factors of MS

A
  • Age: most commonly diagnosed in 20-40 year olds
  • Female gender: MS is 3 times more common in females
  • Smoking
  • Obesity
  • Vitamin D deficiency
  • Northern latitudes
  • Family history: HLA-DR2 is implicated; 30% monozygotic twin concordance
  • Autoimmunity: patients often have a family history of other autoimmune disorders
  • EBV infection: the virus with the greatest link to MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What factors influence who gets MS?

A

Environment
Genetics
Chance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is myelin?

A

Myelin is the protective sheath that surrounds the axons of neurons, allowing them to quickly send electrical impulses.

This myelin is produced by oligodendrocytes in the CNS and by schwann cells in the peripheral nervous system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does demyelination occur in MS?

A

demyelination happens when the immune system inappropriately attacks and destroys the myelin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the pathophysiology of MS?

A
  • T cells enter the blood brain barrier and activated by myelin
  • T cell changes BB barrier and causes expression of more receptors allowing more immune cells to enter
  • immune cells such as macrophages can enter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What type of hypersensitivity reaction is MS

A

Type IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What happens in this type IV reaction?

A

T-cells release cytokines. These can recruit more immune cells as well as directly damaging the oligodendrocytes. B-cell make antibodies and macrophages can use these antibodies to attack the oligodendrocytes, ultimately destroying the myelin. This leaves behind areas of plaque/ sclera.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What can happen initially?

A

At first there may be remyelination but over time there is permanent damage.

A characteristic features of MS is that lesions vary in their location over time, meaning that different nerves are affected and symptoms change over time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the pathogenesis of MS

A

The pathogenesis of MS is not well understood, although it is thought to occur due to environmental triggers in genetically susceptible individuals, comprising an inflammatory and degenerative component.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

The immunopathogenic model of MS

A

Genetic susceptibility + Environmental trigger > Activated auto-reactive T lymphocytes

Activated Autoreactive T lymphocytes activate > Macrophages, polyclonal activated autoreactive T lymphocytes, B lymphocytes and compliment

All of these lead to complete inflammatory attack with demyelination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which components of the immune system are relevant to MS pathogenesis?

A

Lymphocytes - T (CD8, CD4, Suppressor), B (Plasma cells and antibodies)
Macrophages
Complement
Cytokines - interferons, TNF, IL and others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Key features of MS

A
  • Inflammatory, demyelinating disease
  • Specific to CNS
  • Commonest cause of chronic neurological disability in young adults
  • Begins usually 20-40
  • Early course is relapse/ remitting
  • Progressive disability over time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Relapse remitting MS

A
  • The most common pattern (85% of cases)
  • Episodic flare-ups (may last days, weeks or months), separated by periods of remission.
  • More frequent in first 3-4 years
  • There isn’t full recovery after the flare-ups, so disability increases over time
  • 60% of patients develop secondary progressive MS within 15 years
  • Clearly defined - can lead to full recovery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Secondary (Chronic) progressive MS

A

Initially, the disease starts with a relapsing-remitting course, but then symptoms get progressively worse with no periods of remission
Slow, inexorable decline in neurological functions
- from disease onset
- following an initial relapsing/ remitting course

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Primary progressive MS

A
  • Symptoms get progressively worse from disease onset with no periods of remission
  • Accounts for 10% of cases and is more common inolder patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Progressive relapsing MS

A

One constant attack but there are bouts superimposed during which the disability increases even faster

19
Q

Benign MS

A

Few relapses
Little disability

20
Q

What happens in active MS

A

NAME?

21
Q

What happens in inactive MS

A

NAME?

22
Q

If plaque is distributed in cerebral hemispheres what happens

A

Large variety of symptoms but also silent lesions

23
Q

Spinal cord plaque causes?

A

NAME?

24
Q

Visual signs of MS due to plaque distribution and demyelination of optic nerve

A

NAME?

25
Q

Other signs of MS?

A
  • Upper motor neuron signs with spastic paraparesis are common
  • Cerebellar signs: such as ataxia and tremor
  • Sensory loss: due to demyelination of spinothalamic or dorsal columns
  • Trigeminal neuralgia: stimulation to face causes pain
26
Q

Symptoms of MS

A
  • Blurred vision and red desaturation
  • Numbness, tingling and other strange sensations: plaques in the sensory pathways
  • Weakness
  • Bowel and bladder dysfunction: plaques involve the autonomic nervous system
  • Lhermitte’s phenomenon: electric shock sensation on neck flexion, caused by stretching the demyelinated dorsal column.
  • Uhtoff’s phenomenon: worsening of symptoms following a rise in temperature, such as a hot bath
    UMN signs (Not LMN)
    Brainstem signs, sensory signals
27
Q

Plaque in the medulla and pons + Cerebellar white matter cause?

A

M + P= Dysarthria, double vision, vertigo, nystagmus

CWM = Dysarthria, nystagmus, intention tremor, ataxia

28
Q

Atypical signs of MS

A

NAME?

29
Q

First symptoms of MS

A

Weakness, paraesthesia, visual loss

30
Q

Primary investigation for MS

A
  • MRI brain and spine:
    • Demyelinating plaques: periventricular plaques are called Dawson’s fingers
    • High signal T2 lesions
    • Old lesions willnotenhance with contrast, whereas newer lesions will. This provides evidence of dissemination of lesions in time and space which is required for a diagnosis of MS
  • Lumbar puncture for CSF:oligoclonal bands found in the CSF andnotin the serum, increased IgG
  • Visual evoked potentials:responses recorded to visual stimulus using electrodes; **delayed velocity but a normal amplitude
31
Q

What is the diagnostic criteria used to diagnose MS?

A

The McDonald criteria is used to diagnose MS.

In brief, the criteria can be described assymptoms/signs which demonstrate dissemination in space (i.e. different parts of the CNS affected) and time.

32
Q

McDonalds criteria

A

Diagnosis is based on:

  • 2 or more relapsesAND EITHER
    • Objective clinical evidence of 2 or more CNS lesionsOR
    • Objective clinical evidence of one lesionWITHa reasonable history of a previous relapse
  • ‘Objective evidence’ is defined as an abnormality on neurological exam, MRI or visual evoked potentials
33
Q

Management for relapse

A
  • Steroids:
    • Oral or IV methylprednisolone is first-line
    • Steroids reduce relapsedurationby 13 days
  • Plasma exchange: to remove disease-causing antibodies
34
Q

What is the management for those who reduce relapse or demonstrate progression?

A
  • Disease-modifying drugs:
    • Beta-interferon: decreases the level of inflammatory cytokines
    • Monoclonal antibodies e.g. alemtuzumab (anti-CD52) and natalizumab (anti-α4𝛃1-integrin)
    • Glatiramer acetate: immunomodulator drug which acts as a ‘decoy’
    • Fingolimod: a sphingosine-1-phosphate receptor modulator that keeps lymphocytes in lymph nodes so they can’t cause inflammation
35
Q

Betaferon side effects

A

NAME?

36
Q

Management of MS complications

A
  • spasticity: physiotherapy, avoid triggers,baclofen or gabapentinare first-line
    • Alternatives include dantrolene and diazepam, baclofen
  • Neuropathic pain: consider amitriptyline or gabapentin
  • Bladder dysfunction: perform a bladder ultrasound
    • Insignificant residual volume:consider an anticholinergic(e.g. oxybutynin)
    • Significant residual volume:intermittent self-catheterisation
  • Depression: SSRIs
  • Fatigue:investigate other causes (e.g. anaemia), CBT and consideramantadine
37
Q

Treatment for tremor

A

NAME?

38
Q

Treatment for sexual dysfunction in men and women with MS

A
  • Sexual counselling
  • ED - Surgically implanted penile prostheses, injections of papaverine or prostoglandin, oral yohimbine taken 1-2 hours before sex
  • Vibrators, lubricant gels
39
Q

Acute + Sub acute pain syndromes in MS

A

NAME?

40
Q

Chronic pain syndromes

A

NAME?

41
Q

Complications of MS

A
  • Genitourinary:urinary tract infections, urinary retention and incontinence
  • Constipation
  • Depression: offer mental health support if required
  • Visual impairment
  • Mobility impairment: offer physiotherapy, orthotics and other mobility aids
  • Erectile dysfunction
42
Q

DDs for MS

A

Autoimmune disorders- SLE, Sjorgens, polyarteritis nodosa
AIDS
Lyme disease, syphilis
Cardiac embolic event

43
Q

MS prognosis

A

Given the varying disease course, the prognosis varies significantly between patients. Most patients will still be ambulant at 15 years post-diagnosis, whilst the life expectancy for people with MS is around 5 to 10 years lower than average.

Fortunately, the most common presentation of MS has good prognostic features.

Other good prognostic features include:

  • Sensory symptomsalone
  • Complete recoverybetween relapses
  • A long periodbetween thefirst two relapses
44
Q

Features suggestive of re evaluation of MS diagnosis

A

No objective neurological deficits
No eye involvement
Localised disease
No CSF abnormalities